Ncardia’s in-house Cardio.Acute Services provides an acute cardiac safety profile of test compounds based on the electrophysiology of fully functional and validated human cardiomyocytes.

Investigating the electrical activity of hiPSC-CMs’ acute response to drugs is part of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative.* CiPA aims to replace current methods that evaluate proarrhythmic risk with assessments that are more clinically predictive and will improve effective drug development.

Ncardia is an official partner of the CiPA initiative and its Cor.4U® and Pluricyte® Cardiomyocytes are currently being used by different (non-)core partners. Our cardiomyocytes in combination with microelectrode array (MEA) platforms provide a highly relevant and predictive in vitro assay platform to study the cardiac safety profile of compounds during drug development.

*CiPA (Comprehensive in Vitro Proarrhythmia Assay) is a project driven by the Health and Environmental Science Institute (HESI) and the FDA. For more information visit http://cipaproject.org/.



Service specifications

Cell type

iPSC-derived cardiomyocytes



Service type

CiPA-like MEA functional analysis


Up to 96 wells

Assay window

30 Minute compound exposure

Compound concentrations*

0.1, 1, 10 µM in medium + 0.1% DMSO (in triplicates)

Positive controls

hERG channel blocker: Dofetilide 30 nM

Nav 1.5 and hERG channel blocker: Mexiletine 30 µM

Vehicle control

0.1% DMSO


Beat rate, beat rate CoV, field potential duration (FPD), depolarization peak amplitude and proarrhythmic events


3 Weeks (for up to 9 compounds)


A study protocol will be sent to initiate the study. Results are sent as draft and final study report.

*Suggested concentrations, to be agreed with client